Glutamate attenuates the ILC2 response and allergic airway inflammation via the kainate receptor GluK2.

Glutamate suppresses ILC2 responses and reduces allergic airway inflammation via the kainate receptor GluK2 in mice.

• Why it matters: Understanding how glutamate modulates immune cells like ILC2s could reveal new therapeutic targets for allergic asthma, a condition driven by ILC2 activity.
• What they did: Researchers measured lung glutamate levels after allergen exposure, used genetically modified mice to assess glutamate’s effects on ILC2s, and applied transcriptome and metabolic analyses to uncover mechanisms.
• The result: Glutamate inhibits ILC2 activation by targeting GluK2, reducing oxidative metabolism and inflammation; activating GluK2 with BPAM344 suppressed airway inflammation, suggesting GluK2 as a potential therapeutic target.